PTEN inhibitors: An evaluation of current compounds

Laura Spinelli, Yvonne E. Lindsay, Nicholas R. Leslie*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)
160 Downloads (Pure)


Small molecule inhibitors of many classes of enzymes, including phosphatases, have widespread use as experimental tools and as therapeutics. Efforts to develop inhibitors against the lipid phosphatase and tumour suppressor, PTEN, was for some time limited by concerns that their use as therapy could result in increased risk of cancer. However, the accumulation of evidence that short term PTEN inhibition may be valuable in conditions such as nerve injury has raised interest. Here we investigate the inhibition of PTEN by four available PTEN inhibitors, bpV(phen), bpV(pic), VO-OHpic and SF1670 and compared this inhibition with that of only 3 other related enzymes, the tyrosine phosphatase SHP1 and the phosphoinositide phosphatases INPP4A and INPP4B. Even with this very small number of comparators, for all compounds, inhibition of multiple enzymes was observed and with all three vanadate compounds, this was similar or more potent than the inhibition of PTEN. In particular, the bisperoxovanadate compounds were found to inhibit PTEN poorly in the presence of reducing agents including the cellular redox buffer glutathione.

Original languageEnglish
Pages (from-to)102-111
Number of pages10
JournalAdvances in Biological Regulation
Early online date2 Oct 2014
Publication statusPublished - Jan 2015


  • Drug
  • Enzyme
  • Inhibitor
  • Phosphatase
  • Phosphoinositide
  • PI 3-Kinase
  • PTEN


Dive into the research topics of 'PTEN inhibitors: An evaluation of current compounds'. Together they form a unique fingerprint.

Cite this